Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1404&sort=program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=program_officials", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1403&sort=program_officials" }, "data": [ { "type": "Grant", "id": "15769", "attributes": { "award_id": "1K23HL181397-01", "title": "Optimal Ventilator Management in Patients with ARDS on ECMO", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32586, "first_name": "ROYA", "last_name": "KALANTARI", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2030-07-31", "award_amount": 178846, "principal_investigator": { "id": 32840, "first_name": "Mazen Faris", "last_name": "Odish", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2637, "ror": "", "name": "UNIVERSITY OF CALIFORNIA, SAN DIEGO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Research Plan: Acute respiratory distress syndrome (ARDS) is a severe and common condition that affects 10% of patients in the intensive care unit (ICU), and was a major cause of morbidity and mortality during the COVID-19 pandemic. While mechanical ventilation is often necessary for ARDS, it can also induce additional lung injury known as ventilator induced lung injury (VILI). VILI may be minimized by using low tidal volumes/driving pressure and with positive end expiratory pressure (PEEP). Some patients with severe and refractory ARDS require veno-venous extracorporeal membrane oxygenation (V-V ECMO), the highest level of life support which provides oxygen and removes carbon dioxide from the blood using an external device. A major benefit of ECMO is thought to be the ability to minimize VILI; however, the optimal ventilator settings for patients with ARDS on ECMO are not known. Current guidelines use a one-size-fits-all approach. Our central hypothesis is that personalized PEEP adjusted by measuring intrathoracic pressures via esophageal manometry (Pes) will decease VILI as assessed by biomarkers of inflammation (main outcomes IL-6 and sRAGE). To carry out these aims, we plan to prospectively randomize 62 patients with ARDS on V-V ECMO and neuromuscular blockade and perform serial biomarker measurements with PEEP of 10 cmH2O (ECMO guidelines) vs. PEEP guided by esophageal manometry. In addition to biomarkers of VILI, we will assess differences in other physiological outcomes including pulmonary mechanics and gas exchange. Although this proposal focuses on patients on ECMO, we believe the knowledge gained will have relevance for all patients with ARDS. Career Development Plan: The goal of the PI, Dr. Mazen Odish, is to personalize ARDS and ventilator strategies for those on ECMO based on physiology and biomarkers. The PI has an interest in applied physiology and critical care, this award will help him refine these skills and develop new skills in clinical trials, statistics, and patient-oriented research, to test rigorously methods to care for critically ill patients with ARDS with or without ECMO. To obtain these new skills Dr. Odish and his excellent and multi-disciplinary mentoring/advisory team (led by Drs. Owens and Malhotra, plus outstanding statistical and methodologic support) has three main training goals. 1) Pulmonary mechanics and biomarkers during ARDS, 2) control of breathing and measurement of work of breathing during ARDS/mechanical ventilation, and 3) clinical trial design and statistical training. These training activities are tailored for the PI to achieve his goals and maximize career development towards becoming an independent physician scientist. Furthermore, his structured course work will lead to a Masters of Advanced Studies in Clinical Research. Dr. Odish is at the right place and time in his career to align his clinical expertise in ECMO and ARDS with his research goals to understand optimal ventilator settings and therapies. Eventually his work and new skill set may improve the lives of all people suffering from respiratory illness.", "keywords": [ "Acute Respiratory Distress Syndrome", "Advisory Committees", "Affect", "Arteries", "Atelectasis", "Automobile Driving", "Award", "Biological Markers", "Blood", "Body Weight", "Breathing", "COVID-19 pandemic", "Carbon Dioxide", "Clinical", "Clinical Research", "Clinical Trials", "Clinical Trials Design", "Critical Care", "Critical Illness", "Development Plans", "Devices", "Esophagus", "Extracorporeal Membrane Oxygenation", "Functional disorder", "Gases", "Goals", "Guidelines", "Heart and Lung machine", "Heterogeneity", "Hour", "Hypoxemia", "Induction of neuromuscular blockade", "Inflammation", "Injury", "Intensive Care Units", "Interleukin-6", "Knowledge", "Life", "Lung", "Lung Compliance", "Manometry", "Measurement", "Measures", "Mechanical ventilation", "Mechanics", "Mediator", "Mentors", "Meta-Analysis", "Methodology", "Methods", "Morbidity - disease rate", "Multiple Organ Failure", "Organ", "Outcome", "Oxygen", "Patient Care", "Patients", "Persons", "Physicians", "Physiological", "Physiology", "Positive-Pressure Respiration", "Process", "Prone Position", "Pulmonary Gas Exchange", "Randomized", "Recommendation", "Recording of previous events", "Refractory", "Research", "Research Design", "Resolution", "Respiratory Failure", "Respiratory System", "Respiratory physiology", "Rest", "Risk", "Scientist", "Stress", "Structure", "Testing", "Tidal Volume", "Time", "Training", "Training Activity", "Venous", "Ventilator", "Ventilator-induced lung injury", "Vision", "Work", "Work of Breathing", "career", "career development", "esophagus pressure", "healing", "improved", "improved outcome", "individual patient", "interest", "lung injury", "mortality", "multidisciplinary", "patient oriented research", "personalized approach", "pressure", "prevent", "primary outcome", "prospective", "pulmonary", "radiological imaging", "respiratory", "skills", "soluble RAGE", "statistics", "theories", "ventilation" ], "approved": true } }, { "type": "Grant", "id": "15785", "attributes": { "award_id": "1K99HL181185-01", "title": "Investigating Histone Acetylation Modulator Function in Alveolar Regeneration and Disease Pathogenesis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32586, "first_name": "ROYA", "last_name": "KALANTARI", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2027-07-31", "award_amount": 130593, "principal_investigator": { "id": 32865, "first_name": "Dawei", "last_name": "Sun", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2649, "ror": "", "name": "BROAD INSTITUTE, INC.", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Influenza and COVID-19 remain significant global health concerns, with viral infections in the lungs often leading to alveolar damage and, in severe cases, progressing to acute respiratory distress syndrome (ARDS). ARDS development is closely linked to impaired alveolar regeneration, which relies on the proliferation and differentiation of alveolar type 2 (AT2) stem cells into alveolar type 1 (AT1) cells to restore lung function. The precise molecular mechanisms that govern alveolar regeneration remain poorly understood. Here I have established a high-throughput in vivo genetic screening system in mice to systematically search for essential epigenetic modulators that contribute to alveolar regeneration. Preliminary results have identified numerous histone acetylation pathway related genes, including lysine acetyltransferase 8 (Kat8), are required for AT2 restoration and may contribute to differentiation towards AT1 cells. Kat8 has not previously been linked to alveolar regeneration, however, a key component of its associated protein complex and downstream target genes has been identified in genome-wide association studies as risk genes for idiopathic pulmonary fibrosis, a deadly disease also caused by impaired alveolar regeneration. This proposal aims to clarify the mechanisms by which Kat8 regulates alveolar regeneration, determine the association of Kat8 loss of function with pulmonary fibrosis and further enhance the existing in vivo screen system by integration with single cell techniques to comprehensively map other histone acetylation modulation functions. This study will shed light on epigenetic mechanisms underlying AT2-mediated alveolar regeneration and disease pathology, with the potential to inform the design of novel therapeutic approaches targeting histone acetylation modulators to promote alveolar regeneration and combat fibrosis progression. The proposed research plan will be executed at the Broad Institute of MIT and Harvard, Cambridge, under the mentorship of Dr. Fei Chen and Dr. Jayaraj Rajagopal, with overall complementary expertise in the field of genomics, synthetic biology, and lung stem cell biology. My career objective is to become a tenure-track faculty pioneering and simultaneously training next-generation scientists at the intersection of technology and lung stem cell biology. To accomplish my career goals, I have put together a comprehensive training plan to enhance the overall skill sets required to establish myself as a successful independent investigator. To ensure timely progress toward fulfilling my rigorous research plan and career goals, I have gathered an expert advisory committee comprising Dr. Carla Kim, Dr. Darrell Kotton, Dr. Jason Buenrostro, and Dr. Ruth Franklin, with whom I will regularly discuss my research progress and receive invaluable career development guidance, the key ingredient to my pathway to scientific independence.", "keywords": [ "Acetylation", "Acetyltransferase", "Acute Respiratory Distress Syndrome", "Advisory Committees", "Alveolar", "Automobile Driving", "Biological Assay", "COVID-19", "COVID-19 mortality", "Cancer cell line", "Cell Aging", "Cell Differentiation process", "Cell Proliferation", "Cells", "Cessation of life", "Chemicals", "Complex", "Complication", "Dependovirus", "Development", "Disease", "Disease Progression", "Down-Regulation", "Engineering", "Ensure", "Epigenetic Process", "Faculty", "Fibrosis", "Gene Expression", "Genes", "Genetic", "Genetic Markers", "Genetic Screening", "Genome", "Genomics", "Goals", "Guide RNA", "Histone Acetylation", "Histone Deacetylase", "Histone H4", "Homeostasis", "Impairment", "In Vitro", "Influenza", "Knock-out", "Link", "Lung", "Lysine", "Maps", "Mediating", "Mentors", "Mentorship", "Methods", "Mitochondria", "Molecular", "Mouse Embryonic Stem Cells", "Mus", "Mutation", "Natural regeneration", "Pathogenesis", "Pathology", "Pathway interactions", "Phenotype", "Play", "Population", "Process", "Proliferating", "Pulmonary Fibrosis", "Research", "Research Personnel", "Resolution", "Role", "Satellite Viruses", "Scientist", "Stimulus", "System", "Techniques", "Technology", "Telomere Maintenance Gene", "Training", "Transitional Cell", "Variant", "Vertebral column", "Viral Pneumonia", "Virus Diseases", "career", "career development", "cell behavior", "cell type", "combat", "design", "genome wide association study", "global health", "histone acetyltransferase", "idiopathic pulmonary fibrosis", "improved", "in vivo", "insight", "loss of function", "lung injury", "lung stem cell", "male specific", "mitochondrial dysfunction", "mortality", "new therapeutic target", "next generation", "novel therapeutic intervention", "old mice", "progenitor", "protein complex", "pulmonary function", "restoration", "risk variant", "screening", "skills", "stem cell biology", "stem cells", "synthetic biology", "telomere", "tenure track", "transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "15899", "attributes": { "award_id": "4R00HL166870-03", "title": "Targeted mRNA therapies treating ARDS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32586, "first_name": "ROYA", "last_name": "KALANTARI", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-16", "end_date": "2028-07-31", "award_amount": 249000, "principal_investigator": { "id": 28119, "first_name": "Zhengjie", "last_name": "Zhou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1445, "ror": "", "name": "TEMPLE UNIV OF THE COMMONWEALTH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary/Abstract: This proposal describes a research plan for Zhengjie Zhou, Ph.D., for the R00 portion of the NIH mentored career award (K99/R00). The PI is completing training in an NIH K99 fellowship (K99HL166870) and is trained in vascular biology, lung biology, molecular biology, and bioengineering. This proposal tests the overall hypothesis of formulating novel lung-targeting nanoparticles to deliver therapeutic mRNA in a cell-specific manner for the treatment of acute respiratory distress syndrome (ARDS), which is the major cause of death for severe influenza and SARS-CoV-2 infection. Currently, efficient medicines are still lacking for ARDS therapy. ARDS is characterized by the dysfunction of endothelial cells (ECs), epithelial cells, and the following uncontrolled cytokine storm. Based on our recent research about a vascular cell adhesion molecule-1 (VCAM1) targeting nanotherapeutic study, I rationally designed and optimized a targeting lipid nanoparticle (LNP) that enables robust mRNA delivery in vivo in a cell-specific manner. Leveraging this mRNA delivery platform, We propose to (i) promote endothelium health by endothelial cell-specific delivery of KLF2 mRNA to restore KLF2, a transcription factor, that plays a key role in facilitating endothelial health and vasculature homeostasis. KLF2 was demonstrated significantly reduced in mice lungs induced by LPS, influenza H1N1, SARS-CoV-2, and COVID-19 patients lungs; (ii) activate epithelial cells innate immune pathway by epithelium specific delivery of 2’-5’-oligoadenylate synthetase 1 (OAS1) mRNA to augment epithelium interferon (IFN) response through OAS/RNase L pathway to defense respiratory viral infection. Our data demonstrated that KLF2 mRNA/VCAM1-targeting LNP targeted the inflamed mice lungs endothelium and significantly reduced the ARDS induced by H1N1. Our preliminary data demonstrated that the OAS1 mRNA/epithelium-targeting LNP targeted the mice inflamed lung epithelium and significantly reduced the H1N1 replication and lung ARDS. Aim 1 will comprehensively evaluate the therapeutic potency of VCAM1-targeting LNP to restore endothelial KLF2 and lessen ARDS in a clinically relevant rat ARDS model induced by high-tidal ventilation (HTV). Aim 2 will determine how epithelium-targeted delivery of OAS1 activates the innate immune response and exerts antiviral effects in mice by OAS1 mRNA/epithelium-targeting LNP, and will determine its therapeutic effect to treat respiratory virus-induced ARDS. Successful completion of these projects will provide a promising mRNA therapeutic treating lung disease and provide an “effective responder” in viral pandemics, regardless of virus evolution and mutation. This mRNA delivery platform is adaptable and potentially beneficial for various cardiovascular diseases.", "keywords": [ "2019-nCoV", "Acute Lung Injury", "Acute Respiratory Distress Syndrome", "Address", "Alveolar", "Anti-viral Agents", "Anti-viral Response", "Arteries", "Automobile Driving", "Award", "Bacteria", "Binding", "Biology", "Biomedical Engineering", "Blood Vessels", "COVID-19 mortality", "COVID-19 patient", "Cardiovascular Diseases", "Cause of Death", "Cells", "Community Medicine", "Critical Illness", "Data", "Doctor of Philosophy", "Edema", "Encapsulated", "Endothelial Cells", "Endothelium", "Engineering", "Epithelial Cells", "Epithelium", "Event", "Evolution", "Experimental Designs", "Fellowship", "Formulation", "Functional disorder", "Future", "Health", "Homeostasis", "Human", "Inflammation", "Inflammatory", "Influenza", "Influenza A Virus H1N1 Subtype", "Innate Immune Response", "Interferons", "Kruppel-like transcription factors", "Lead", "Ligase", "Lung", "Lung Diseases", "Lung infections", "Mechanical ventilation", "Medical", "Medicine", "Mentors", "Messenger RNA", "MicroRNAs", "Modeling", "Molecular Biology", "Molecular Profiling", "Morbidity - disease rate", "Mus", "Mutation", "Pathogenesis", "Pathway interactions", "Patients", "Permeability", "Pharmacotherapy", "Play", "Proteins", "Publishing", "Pulmonary Edema", "Pulmonary Inflammation", "Pulmonary alveolar structure", "Rattus", "Research", "Ribonucleases", "Role", "SARS-CoV-2 infection", "Small RNA", "Testing", "Therapeutic", "Therapeutic Effect", "Therapeutic Studies", "Tidal Volume", "Training", "United States National Institutes of Health", "Vascular Cell Adhesion Molecule-1", "Vascular Endothelial Cell", "Vascular Endothelium", "Viral", "Viral Respiratory Tract Infection", "Virus", "Virus Diseases", "Virus Replication", "Water", "alveolar epithelium", "career", "clinically relevant", "cytokine release syndrome", "endothelial dysfunction", "in vivo", "influenzavirus", "inhibitor", "innate immune pathways", "innovation", "lipid nanoparticle", "lung injury", "mRNA delivery", "monolayer", "mortality", "nanomedicine", "nanoparticle", "nanotherapeutic", "novel", "oligoadenylate", "protein function", "pulmonary", "pulmonary vascular disorder", "rational design", "respiratory virus", "response", "restoration", "stem", "targeted delivery", "therapeutic effectiveness", "therapeutic evaluation", "transcription factor", "vascular endothelial dysfunction", "ventilation", "viral RNA", "viral pandemic" ], "approved": true } }, { "type": "Grant", "id": "15717", "attributes": { "award_id": "2514067", "title": "CAREER: Advancing academic cultures of well-being by understanding professional experiences of engineering faculty", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "EngEd-Engineering Education" ], "program_reference_codes": [], "program_officials": [ { "id": 32596, "first_name": "Alice", "last_name": "Pawley", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-02-15", "end_date": null, "award_amount": 575430, "principal_investigator": { "id": 13160, "first_name": "James", "last_name": "Huff", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 160, "ror": "", "name": "University of Georgia Research Foundation Inc", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "In the COVID-19 pandemic, we have all come to recognize the importance of promoting well-being in every facet of life, including and especially in higher education. We recognize that promoting well-being among faculty and students must be a central focus rather than an afterthought of professional education. Accordingly, this project will advance cultures of well-being in engineering education by understanding faculty members’ personal experiences of coping with negative emotions and failure within their professional context. Engineering faculty members are highly influential to students who seek their guidance to understand what it means to become an engineer. Faculty are best positioned to influence equitable, inclusive, and healthy cultures of engineering education when their own emotional needs are met. Therefore, this project will examine how faculty members meet their well-being needs and how they use their influence to nurture or inhibit cultures that allow for engineering students to experience well-being. This project aims to transform how faculty relationally connect with students and other faculty and staff by transforming the ways that they understand themselves. In addition to the research plan, which includes intensive interviews with engineering faculty at multiple institutions, this project will also provide direct training to faculty on coping with failures and preserving a positive professional identity. In line with the PI’s career mission, this project will develop and define a scholarship of care within engineering education research that influences national and local policies of well-being through research-informed insights. Specifically, this project will address two significant gaps in extant literature: 1) the role of failure and negative emotions in facilitating or mitigating cultural patterns of well-being; 2) the complex, dynamic nature of the lived emotional experiences of engineering faculty. This project is organized around the following objectives: Objective 1: Examine social and individual experiences of failure and negative emotions in engineering faculty. Objective 2: Characterize the link between faculty’s emotional experience and their surrounding cultures of well-being. Objective 3: Establish a framework to provide training for engineering programs to establish cultures that support healthy strategies for coping with professional failure. This project will use a qualitative mixed-methods approach that embeds an interpretative phenomenological analysis (IPA) study that examines the lived experiences of professional failure and negative emotions in engineering faculty (Objective 1) within a constructivist grounded theory (CGT) analysis that generates a theoretical model of the relationships between faculty emotional regulation and cultures of well-being (Objective 2). The education plan to develop faculty training on regulating emotions related to professional failure (Objective 3) will be interwoven with the research focus to change cultures of well-being (Objective 2). This study will occur at three purposefully selected institutions and involve 10-12 faculty participants for the IPA study, 18-22 participants that are interviewed twice for the CGT study (36-44 total interviews), and a three-module training series to be delivered at four institutions. This project is jointly funded by Broadening Participation in Engineering (BPE) in the Engineering Education and Centers (EEC) Division of Engineering (ENG), and the Established Program to Stimulate Competitive Research (EPSCoR). This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15718", "attributes": { "award_id": "1R01AI190359-01", "title": "Effects of Vaccination on Acute and Post-Acute Respiratory Viral Infection Outcomes in Solid Organ Transplant Recipients", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32597, "first_name": "BROOKE ALLISON", "last_name": "BOZICK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-13", "end_date": "2030-05-31", "award_amount": 1442898, "principal_investigator": { "id": 32598, "first_name": "William", "last_name": "Werbel", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Respiratory viral infections (RVI) including SARS-CoV-2, RSV, and influenza, are major threats to the health of solid organ transplant recipients (SOTRs), who live at the intersection of chronic comorbidity, frailty, and heavy immunosuppression. These factors contribute to high rates of clinically observed severe RVI and pose risks for poorly understood post-acute syndromes including organ dysfunction and protracted infections associated with immune evasive mutations of", "keywords": [ "2019-nCoV", "Accounting", "Acute", "Address", "Age", "Allografting", "Antibody Response", "Antimetabolites", "Authorization documentation", "Binding", "Biological Assay", "Blood specimen", "COVID-19", "COVID-19 pandemic", "COVID-19 vaccination", "Cessation of life", "Chronic", "Clinical", "Data", "Detection", "Development", "Diagnosis", "Disease", "Dose", "Enrollment", "Event", "Exclusion", "Frequencies", "Functional disorder", "Health", "Heterogeneity", "Hospital Mortality", "Hospitalization", "Immune Evasion", "Immunocompromised Host", "Immunoglobulin G", "Immunologics", "Immunosuppression", "Immunosuppressive Agents", "Infection", "Influenza", "Influenza A Virus H1N1 Subtype", "Intervention", "Knowledge", "Liquid substance", "Long COVID", "Longitudinal cohort", "Lung", "Measures", "Modeling", "Morbidity - disease rate", "Mucosal Immune Responses", "Mucosal Immunity", "Mucous Membrane", "Mutation", "Nose", "Organ", "Outcome", "Outcome Measure", "Participant", "Pattern", "Persons", "Phenotype", "Plasma", "Policies", "Population", "Prospective Studies", "Prospective cohort", "Public Health", "Regimen", "Reporting", "Research", "Respiratory Syncytial Virus Vaccines", "Risk", "Risk Assessment", "Risk Factors", "Sampling", "Schedule", "Secretory Immunoglobulin A", "Severity of illness", "Signal Transduction", "Solid", "Subgroup", "Surveys", "Swab", "Symptoms", "Syndrome", "Time", "Transplantation", "Vaccination", "Vaccine Antigen", "Vaccines", "Viral", "Viral Respiratory Tract Infection", "Virus Diseases", "Virus Shedding", "breakthrough infection", "chronic infection", "cohort", "comorbidity", "effectiveness evaluation", "experience", "frailty", "high risk", "immunogenic", "immunoprophylaxis", "improved", "infection burden", "infection risk", "influenza infection", "mortality", "nasal swab", "neutralizing antibody", "novel", "novel vaccines", "organ transplant recipient", "organ transplant rejection", "post SARS-CoV-2 infection", "programs", "prospective", "response", "vaccine effectiveness", "vaccine platform", "vaccine response", "vaccine trial" ], "approved": true } }, { "type": "Grant", "id": "15738", "attributes": { "award_id": "1R21AI183025-01A1", "title": "Endoplasmic Reticulum (ER)-phagy in Influenza Infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32597, "first_name": "BROOKE ALLISON", "last_name": "BOZICK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-12", "end_date": "2027-07-31", "award_amount": 433423, "principal_investigator": { "id": 2476, "first_name": "Vikas", "last_name": "Anathy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2609, "ror": "", "name": "UNIVERSITY OF VERMONT & ST AGRIC COLLEGE", "address": "", "city": "", "state": "VT", "zip": "", "country": "United States", "approved": true }, "abstract": "Influenza infection in susceptible patients results in a higher viral load, cytokine storm, tissue damage, lung function decline, and mortality. It is well known that interferons control influenza burden and inflammatory responses. However, mechanistic understandings of IFN-mediated regulation of influenza burden in the lung epithelial cells is unclear. We have identified a novel association between Endoplasmic Reticulum (ER)-specific-autophagy response, termed ER- phagy, as regulators of the influenza burden in lung epithelial cells. Characterizing the epithelial ER-Phagy-IFN axis in influenza infection will be the focus of the current application. Unraveling this axis in lung epithelial cells provides much-needed mechanistic insights into controlling viral burden and mitigating virus-induced lung injury. Our preliminary data suggest that levels of ER- phagy receptors in lung epithelial cells regulate viral burden in an IFNβ dependent manner. Based on these novel data, we hypothesize that lung epithelial cells upregulate IFNβ- and IRE1- dependent ER-phagy to diminish viral burden. We will test this hypothesis in the following specific aims: In specific aim 1, we will determine that specific ER-phagy receptors are required to decrease influenza burden in epithelial cells and subsequent lung injury. Aim 2 will use epithelial-specific knockouts of IFNAR1 receptor and recombinant interferons to determine that the type-I IFNs regulate ER-phagy activity post-IAV infection to control IAV burden and lung injury. These studies will determine that the ER-Phagy-IFN axis acts as a first line of defense in the primary site of influenza infection (epithelial cells) to decrease the IAV burden and subsequent lung injury.", "keywords": [ "Ablation", "Affect", "Architecture", "Autophagocytosis", "Autophagosome", "Cell Physiology", "Cells", "Data", "Endoplasmic Reticulum", "Epithelial Cells", "Epithelium", "Functional disorder", "Future", "Human", "Infection", "Inflammatory Response", "Influenza", "Influenza A virus", "Injury", "Interferon-α", "Interferons", "Knock-out", "Link", "Literature", "Lung", "Lysosomes", "Measures", "Mediating", "Monitor", "Mus", "Organelles", "Pathway interactions", "Patients", "Phagosomes", "Predisposition", "Process", "Proteome", "Recombinant Interferon", "Regulation", "Respiratory Failure", "Role", "Site", "Stimulus", "Stress", "Testing", "Tissues", "Upregulation", "Viral", "Viral Load result", "Viral Proteins", "Virus", "Virus Diseases", "airway epithelium", "cell type", "cytokine release syndrome", "epithelial injury", "flu", "influenza infection", "insight", "interferon alpha receptor", "lung injury", "mortality", "novel", "patient population", "pulmonary function decline", "receptor", "response", "smooth endoplasmic reticulum membrane" ], "approved": true } }, { "type": "Grant", "id": "15775", "attributes": { "award_id": "1R01AI193318-01", "title": "Assessing the mechanisms underlying female sex-predominance in Long COVID", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32597, "first_name": "BROOKE ALLISON", "last_name": "BOZICK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-22", "end_date": "2030-07-31", "award_amount": 913012, "principal_investigator": { "id": 31372, "first_name": "Michael Joseph", "last_name": "Peluso", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32848, "first_name": "Nadia R", "last_name": "Roan", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2635, "ror": "", "name": "UNIVERSITY OF CALIFORNIA, SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Long COVID, or post-acute sequelae of COVID-19 (PASC), is estimated to occur after ~10% of COVID-19 cases and affects tens of millions of people worldwide. The mechanisms underlying Long COVID remain poorly understood, which hinders the ability to establish effective evidence-based treatments for the condition. One of the most striking observations in the epidemiology of Long COVID is its female sex predominance: women, particularly pre-menopausal women, are much more likely than men to have the condition. In this proposal, we leverage the Long-term Impact of Infection with Novel Coronavirus (LIINC) cohort (NCT04362150) – which since April 2020 has recruited >1,000 participants with and without Long COVID – to interrogate the mechanistic basis underlying the increased prevalence of Long COVID in women. Our central hypothesis is that in women with Long COVID, there is an elevated and sustained immune type I IFN (T1IFN) response to SARS-CoV-2 (SCV2) gene products, which in turn diminishes the quality of adaptive immune responses against chronic herpesviruses (EBV, CMV) and SCV2 itself, increases the risk of pathogenic autoantibody responses, and results in overall systemic inflammation and immune dysregulation that is characteristic of Long COVID. We further postulate that both incomplete X chromosome inactivation and sex hormones drive the elevated T1IFN responses in women with Long COVID. In Aim 1, we will subject banked longitudinal blood specimens from women and men from LIINC (including both those with and without Long COVID) to assays that will measure the extent of persistent SCV2, T1IFN responses, the features of adaptive immune responses to persistent viruses associated with Long COVID (SCV2, EBV, CMV), autoantibody responses, and the overall state of inflammation. In Aim 2, we will leverage the LIINC Tissue Biopsy program to obtain paired endometrial and gut biopsies from women with Long COVID, to test the hypothesis that the endometrium is a key site of SCV2 persistence and immune dysregulation during Long COVID. This analysis will be compared to a parallel set of studies using gut specimens from matched men with Long COVID. Finally, Aim 3 will analyze specimens from two clinical trials designed to eliminate SCV2 gene products as treatment for Long COVID. The first of these, performed by Resolve Therapeutics, found that administration of RSLV-132, a catalytically active RNase1 intended to degrade SCV2 RNA, improved Long COVID symptoms in women but not men (NCT04944121). The second, occurring within LIINC, is ongoing (enrollment is complete) and testing the effects of AER002, a monoclonal antibody that directly targets and clears SCV2 protein (NCT05877508). Using specimens from both trials, we will test the notion that SCV2 gene products drive sustained T1IFN responses in women that contribute to Long COVID symptoms. Collectively, our aims will improve our understanding of the mechanisms underlying the female-predominance of Long COVID and improve our overall understanding of the disease. This will be a key step in the identification of evidence-based treatments for both women and men who continue to develop and live with this disabling condition.", "keywords": [ "2019-nCoV", "Acute", "Affect", "Age", "Antibodies", "Antibody Response", "Antigens", "Autoantibodies", "Autoimmunity", "Biological", "Biological Assay", "Biology", "Biopsy", "Biopsy Specimen", "Blood", "Blood specimen", "Body System", "COVID-19", "COVID-19 impact", "COVID-19 prevalence", "Characteristics", "Chronic", "Clinical Trials", "Clinical Trials Design", "Cytomegalovirus", "Data", "Disabling condition", "Disease", "Disproportionately impacts women", "Endometrial", "Endometrium", "Enrollment", "Epidemiology", "Estradiol", "Evidence based treatment", "Exhibits", "Fatigue", "Female", "Functional impairment", "Genes", "Genitourinary system", "Gonadal Steroid Hormones", "Health", "Herpesviridae", "High Prevalence", "Human Herpesvirus 4", "Immune", "Immune System Diseases", "Immune response", "Immunity", "Individual", "Infection", "Inflammation", "Inflammatory", "Inflammatory Response", "Interferons", "Intervention", "Intervention Trial", "Link", "Long COVID", "Longitudinal Studies", "Measurement", "Measures", "Monoclonal Antibodies", "Nature", "Observational epidemiology", "Organ", "Outpatients", "Paper", "Participant", "Pathway interactions", "Persons", "Phenotype", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Premenopause", "Prevalence", "Progesterone", "Proteins", "Publishing", "RNA", "Research Infrastructure", "Risk", "SARS-CoV-2 infection", "SARS-CoV-2 inhibitor", "Sex Differences", "Signal Transduction", "Site", "Specimen", "Symptoms", "T cell response", "TLR7 gene", "Testing", "Testosterone", "Therapeutic", "Tissues", "Vaccination", "Viral", "Virus", "Virus Diseases", "Woman", "Women's prevalence", "X Inactivation", "acute COVID-19", "adaptive immune response", "brain fog", "cohort", "common symptom", "design", "experience", "female reproductive tract", "gene product", "improved", "interest", "longitudinal analysis", "men", "mucosal site", "novel coronavirus", "pathogenic autoantibodies", "programs", "prospective", "randomized trial", "recruit", "repository", "response", "sex", "single-cell RNA sequencing", "systemic inflammatory response", "therapy design", "transcriptome", "women's outcomes" ], "approved": true } }, { "type": "Grant", "id": "15824", "attributes": { "award_id": "1U01AI191995-01", "title": "Phase 1 study of a SARS-CoV-2 vaccine adjuvanted via controlled biodistribution of mRNA encoding spike protein and IL-12p70", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32597, "first_name": "BROOKE ALLISON", "last_name": "BOZICK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-25", "end_date": "2030-07-31", "award_amount": 1673641, "principal_investigator": { "id": 44236, "first_name": "Lindsey Robert", "last_name": "Baden", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44237, "first_name": "David James", "last_name": "Dowling", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3368, "ror": "", "name": "BOSTON CHILDREN'S HOSPITAL", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "mRNA-lipid nanoparticle (LNP)-based vaccines are an exciting platform that made advances in combating the pandemic viruses. However, currently licensed mRNA-LNP vaccines approaches are limited in their ability to induce long lived antibody durability, degree of protection varies by age, and levels of cell mediated immunity (CMI) are suboptimal. mRNA vaccine self-adjuvantation is lower in aged individuals, with impaired immune activation upon exposure, inducing insufficient immunity with consequential impaired protection. To try to advance solutions, our published and unpublished work focus on two major novel mRNA vaccine innovations. One is a multi-organ protection (MOP) mRNA sequence homologous to tissue-specific micro-RNAs and enable tissue- specific mRNA translation, constraining expression to the site of injection. Secondly, a biological mRNA-encoded molecular adjuvant precisely guides immunity through inducing the potent and Th1-polarizing analyte, IL-12p70. Based on promising SARS-CoV-2 spike-trimer specific humoral and CMI, in young and aged murine models, and protection from viral challenge in non-human primates (NHPs), the goal of this U01 IICT application is to evaluate a mRNA encoding molecular adjuvant, delivered alongside MOP technology, in the context of a SARS-CoV-2 vaccine. Spike-MOP (CTx892) and IL-12-MOP (CTx672) are first-in-human evaluations, so to assess safety and tolerability, we would first perform dose escalations for CTx892 (stage 1A) and CTx 672 (stage 1B). Based on tolerability, doses less than maximal tolerated CTx892 are chosen to expand sample size for subsequent immunogenicity and mechanism studies. In stage 2, two different doses of CTx 892 will be paired with an escalating CTx672 (IL-12-MOP, e.g., 0.1, 1 µg) dose to assess adjuvanticity along with local and systemic safety and tolerability. Additionally, humoral immunity will be quantified with Spike-specific total IgG (titer and pre-immunization fold- change), IgG1 and IgG3 (Th1 markers), and IgG4 (Th2 marker), with surrogate virus, pseudo- virus, and true viral neutralization. Cellular immunity will include innate assessment in the days after, and adaptive CD4, CD8, and B cell immunity in the weeks, post-immunization. Further readouts include dried blood spots in the hours post-injection to assess proteomic kinetics. In Stage 3, biopsies of lymph node at ~14 days post-immunization and bone marrow at 6 months post-immunization will enable in-depth immunophenotyping and quantification of long-lived plasma cell (LLPC) responses. Durability of humoral and cellular immunity will be probed with a 6-month follow-up sampling of peripheral blood, IL-12-sustained humoral and cellular immunity.", "keywords": [ "2019-nCoV", "Adjuvant", "Adjuvanticity", "Adult", "Age", "Antibodies", "Antigens", "B-Lymphocyte Epitopes", "B-Lymphocytes", "Biodistribution", "Biological", "Blood", "Bone Marrow", "CD8B1 gene", "COVID-19 vaccine", "Cellular Immunity", "Communicable Diseases", "Data", "Dose", "Dryness", "Encapsulated", "Enrollment", "Epitopes", "Evaluation", "Future", "Gene Silencing", "Goals", "Health", "Hour", "Human", "Humoral Immunities", "IgG1", "IgG3", "IgG4", "Immune", "Immune response", "Immunity", "Immunization", "Immunologics", "Immunophenotyping", "Impairment", "Injections", "Interleukin-12", "Interleukins", "Investigation", "Kinetics", "Licensing", "Malaise", "Maximum Tolerated Dose", "Measurement", "Measures", "Messenger RNA", "MicroRNAs", "Molecular", "Myocarditis", "Older Population", "Organ", "Participant", "Pathway interactions", "Pfizer-BioNTech COVID-19 vaccine", "Phase I Clinical Trials", "Plasma", "Plasma Cells", "Proteins", "Proteomics", "Publishing", "RNA vaccine", "Randomized", "Risk", "SARS-CoV-2 spike protein", "Safety", "Sample Size", "Sampling", "Seasons", "Sequence Homologs", "Site", "Spottings", "System", "Technology", "Tissues", "Transcript", "Translations", "Vaccine Adjuvant", "Vaccines", "Viral", "Virus", "Virus Diseases", "aged", "aging population", "clinically relevant", "design", "first-in-human", "follow-up", "immune activation", "immunogenicity", "improved", "innovation", "life span", "lipid nanoparticle", "lymph node biopsy", "lymph nodes", "mRNA Translation", "mRNA lipid nano particle vaccine", "mouse model", "next generation", "nonhuman primate", "novel", "older adult", "pandemic virus", "peripheral blood", "phase 1 study", "primary outcome", "research clinical testing", "respiratory", "response", "safety assessment", "safety testing", "transcriptomics", "unpublished works", "vaccination strategy", "vaccine candidate", "vaccine strategy", "young adult" ], "approved": true } }, { "type": "Grant", "id": "15883", "attributes": { "award_id": "1K24AI187743-01", "title": "Determinants of Vaccine Responses in Low-Income Countries (LICs)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32597, "first_name": "BROOKE ALLISON", "last_name": "BOZICK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-01", "end_date": "2030-08-31", "award_amount": 176738, "principal_investigator": { "id": 7688, "first_name": "Clarissa", "last_name": "Valim", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 860, "ror": "", "name": "BOSTON UNIVERSITY MEDICAL CAMPUS", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "By mentoring junior investigators from the United States and low-come countries (LICs) in patient- oriented research (POR) in global health, particularly in vaccine-preventable diseases, I hope to build local capacity, improve outcomes and reduce health disparities. Working within the resource-limited health systems in LICs is challenging, and the influences of co-infections (particularly parasitic infections), anemia, undernutrition, and various microorganisms on vaccine efficacy may be underappreciated. For these reasons, vaccines and vaccine campaigns developed for and assessed in high-income countries (HICs) cannot be assumed to be feasibly implemented or to perform similarly in LICs. For instance, SARS-CoV-2 vaccination with mRNA-based vaccines in sub-Saharan Africa has been limited by the cold-chain requirement of these vaccines. Cultural and socio-economic factors have led Malawians to generally choose receiving the single dose Ad26.COV2-S rather than the ChAdOx1 vaccine. Growing evidence suggests that performance of vaccines in LICs is lower than HICs and the protective immunity elicited by some vaccines is shorter than originally anticipated. In an interconnected world where diseases do not have borders, optimizing interventions to control transmittable diseases in LICs impacts the health of populations worldwide. The overall goal is to train junior investigators across disciplines to optimize vaccinations in Malawi, a sub-Saharan African country in which I have established a thriving research infrastructure. The first two aims of this application, supported by my R01AI164686-funded project, will assess i) the longevity of antibodies (magnitude and function) and memory cells induced by the Ad26.COV2-S SARS-CoV-2 vaccine; ii) the contribution of pre-existing changes in innate immunity to these responses; iii) the association of malaria, micronutrient deficiency, and microorganisms colonizing the nasopharynx with these responses. In the third aim, funded through this proposal, we will address the longevity of five childhood vaccines, focusing particularly on optimizing the timing of re-vaccination. The importance of this question became obvious in 2023 when three poliovirus cases were identified in Malawi. The Ministry of Health, with no relevant data available, decided to revaccinate all children with an arbitrary cutoff of 15 years of age. I have mentored several investigators in POR, particularly from Malawi, and have been conducting research in the immunoepidemiology of vaccines in LICs (including Malawi) since 2015. With this award, I would be able to expand my panel of trainees, devote more time to each of them, acquire training to further my mentorship skills as well as my own professional skillset, and expand the focus of the research to include other childhood vaccines. With the research infrastructure built in Malawi, I am now well-equipped to successfully train clinician scientists and other junior investigators in POR in infectious diseases, particularly in vaccines in LICS.", "keywords": [ "10 year old", "15 year old", "2019-nCoV", "Adjuvant", "Affect", "Africa South of the Sahara", "African", "American", "Anemia", "Antibiotic Resistance", "Antibodies", "Antibody Response", "Award", "B-Lymphocytes", "Bacteria", "Binding", "COVID-19 morbidity", "COVID-19 vaccination", "COVID-19 vaccine", "Cells", "Child", "Childhood", "Clinical Investigator", "Cold Chains", "Communicable Diseases", "Contracts", "Country", "Data", "Deceleration", "Dedications", "Development", "Discipline", "Disease", "Dose", "Exposure to", "Fever", "Fostering", "Frequencies", "Funding", "Goals", "Grant", "Haemophilus influenzae type b", "Health", "Health system", "Human", "Human poliovirus", "Immune response", "Immunity", "Immunologic Epidemiology", "Income", "Individual", "Infection", "Innate Immune Response", "Intervention", "Knowledge", "Lead", "Longevity", "Malaria", "Malaria Vaccines", "Malawi", "Malnutrition", "Measles", "Measles Vaccine", "Memory", "Mentors", "Mentorship", "Micronutrients", "Mid-Career Clinical Scientist Award (K24)", "Morbidity - disease rate", "Nasopharynx", "Natural Immunity", "Oropharyngeal", "Parasitic infection", "Performance", "Pertussis", "Pertussis Vaccine", "Pilot Projects", "Policies", "Population", "RNA vaccine", "Reduce health disparities", "Research", "Research Infrastructure", "Research Personnel", "Resources", "Risk", "Risk Factors", "Rotavirus", "Rotavirus Vaccines", "SARS-CoV-2 infection", "SARS-CoV-2 transmission", "Sahara", "School-Age Population", "Scientist", "Severities", "Socioeconomic Factors", "Supplementation", "Tetanus", "Tetanus Vaccine", "Time", "Training", "United States", "Vaccination", "Vaccinee", "Vaccines", "Virus", "Work", "Zinc deficiency", "adaptive immune response", "adaptive immunity", "antibody-dependent cell cytotoxicity", "biological systems", "booster vaccine", "career", "co-infection", "global health", "improved outcome", "interest", "international center", "iron deficiency", "low income country", "malaria infection", "microbiome", "micronutrient deficiency", "microorganism", "mortality", "novel vaccines", "pathogen", "patient oriented research", "population health", "prevent", "programs", "response", "skills", "vaccine efficacy", "vaccine response" ], "approved": true } }, { "type": "Grant", "id": "15959", "attributes": { "award_id": "1R21AI196878-01", "title": "A Microfluidic-Free Droplet Technology for Rapid and Quantitative Airborne Pathogen Monitoring", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32597, "first_name": "BROOKE ALLISON", "last_name": "BOZICK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-01", "end_date": "2028-03-31", "award_amount": 451000, "principal_investigator": { "id": 44406, "first_name": "Daniel", "last_name": "Weisgerber", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2635, "ror": "", "name": "UNIVERSITY OF CALIFORNIA, SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Pathogen transmission via indirect routes such as fomite, waterborne, and airborne transmission are hallmarks of both endemic and pandemic spread. Viruses such as Influenza, SARS-CoV-2, and measles are notable examples, in addition to deadly microbes such as Bordetella pertussis, Mycobacterium tuberculosis, and Coccidioides species. However, the rapid detection and analysis of airstreams as part of biosurveillance, public health monitoring, or epidemiological research remains challenging. Current state-of-the-art methods rely on bulky apparatuses for both the collection and detection of airborne agents; most of these methods are ill suited to rapid response point-of-testing within medical facilities, workplace locals, or public spaces. Further, these technologies are based on bulk Polymerase Chain Reaction (PCR) and Loop-mediated isothermal amplification (LAMP) methods that have limited quantitative accuracy. Thus, more portable and accurate platforms are needed to address the types of rapid response and ubiquitous monitoring that is required to minimize outbreaks in the 21st century. Towards this objective, this grant will address the need for an improved method of airborne pathogen detection through the development of the digital droplet Aerosol Capture & Quantification (ddACQ) system. The ddACQ system consists of two novel technologies, a filter particle array and a droplet buoyancy counter. The filter particle array allows for the capture of airborne pathogens or biological agents and generation of microfluidic droplets when mixed with an oil and water reagent solution. A phone-powered heat block then drives a one-step isothermal digital droplet reaction. Digital techniques have several key advantages over classical quantitative PCR and LAMP techniques, namely single molecule detection and direct quantification without a standard curve. Finally, the droplet buoyancy counter allows for smartphone based read out of the reaction immediately at the testing site in under an hour. Together, the innovations within and implementation of the ddACQ system represents a novel application of microfluidic principles and an enabling technology for both pathogen transmission research and public health monitoring applications.", "keywords": [ "2019-nCoV", "Address", "Aerosols", "Air", "Air Movements", "Biological Assay", "Biological Monitoring", "Biological Products", "Bordetella pertussis", "COVID-19", "Cellular Phone", "Characteristics", "Coccidioides", "Collection", "Complex", "Detection", "Development", "Devices", "Disease Outbreaks", "Elements", "Epidemiologic Research", "Etiology", "Generations", "Goals", "Grant", "Heating", "Hour", "Human Resources", "Hydrogels", "Individual", "Influenza", "Influenza A virus", "Influenza B Virus", "Lighting", "Measles", "Measurement", "Measures", "Mediating", "Medical", "Methods", "Microbe", "Microfluidics", "Microscope", "Modeling", "Modernization", "Monitor", "Mycobacterium tuberculosis", "Oils", "Pathogen detection", "Polymerase Chain Reaction", "Public Health", "Quarantine", "Reaction", "Reagent", "Recovery", "Research", "Route", "Running", "Sampling", "Site", "Stream", "Structure", "Surface", "Syndrome", "System", "Techniques", "Technology", "Telephone", "Testing", "Training", "Virus", "Water", "Workplace", "aerosolized", "air sampling", "biosecurity", "contaminated water", "cost", "design", "detection platform", "digital", "experience", "improved", "innovation", "instrumentation", "isothermal amplification", "method development", "new technology", "novel", "pandemic disease", "particle", "pathogen", "pathogenic bacteria", "pathogenic fungus", "portability", "rapid detection", "rapid testing", "respiratory", "respiratory virus", "response", "risk stratification", "single molecule", "targeted agent", "transmission process", "waterborne" ], "approved": true } } ], "meta": { "pagination": { "page": 1404, "pages": 1424, "count": 14236 } } }